CYduct Diagnostics clarifies that the intellectual property referenced in its June 9, 2025 press release relates to a U.S. patent application that has received a Notice of Allowance and is currently in the final administrative approval process with the USPTO. Formal issuance of the patent is expected upon completion of this process. All technology descriptions and development plans remain unchanged.
Correction: CYduct Diagnostics Granted Patent for Precision Medicine Test
Earlier from Cyduct Diagnostics
- Groundbreaking Study on Risk Assessment of Breast Cancer Aims to Revolutionize Diagnosis and Treatment
- Cyduct Diagnostics To Participate at the 10th Annual Yale Innovation Summit
- CYduct Diagnostics Announces Positive Study Results for Biomarker Combinations in the Assessment of Breast Cancer
- CYduct Diagnostics Proudly Supports the "Find It Early Act" to Advance Women's Health